Actionable news
All posts from Actionable news
Actionable news in PETX: Aratana Therapeutics, Inc.,

William Blair Positive On Aratana Therapeutics Inc (PETX) Following FDA Approval For Nocita

William Blair analyst John Kreger reiterates an Outperform rating on shares of Aratana Therapeutics Inc (NASDAQ:PETX), following the news that the pet medicine maker received FDA approval for pipeline drug Nocita, a liposomal formulation of bupivacaine formerly known as AT-00, to treat postoperative pain in dogs. Nocita’s approval follows two other new animal drugs Galliprant, intended to control pain and inflammation associated with osteoarthritis in dogs, and Entyce, indicated for appetite stimulation in dogs.

In light of this approval, Kreger anticipates PETX’s primary focus will shine on commercial execution throughout these next 12 to 18 months. Though Nocita is PETX’s third in...